Chargement de l’entreprise
Just reported
Q3 2026 results
From West Pharmaceutical Services's results release of 29 octobre 2026; its quarterly report has since been filed.
Revenue
Actual
874,5M $US
+8,7 % y/y
+0,3 % q/qGuided
827,5M $US
midpoint
Above guide+5,7 %EPS, GAAP
Actual
3,02 $US
+57 % y/y
+40 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
267,4M $US
+60 % y/y
+49 % q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue3,41B $US – 3,42B $US+11 % y/y Raised +1,6 %
- EPS, adjusted9,38 $US – 9,48 $USRaised +5,4 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes West Pharmaceutical Services is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.153,8B $USA+
MDLNMedline Inc.51,9B $USA
ALCAlcon Inc.36,1B $USA
BLCOBausch & Lomb Corp7,5B $USA-
ATRCAtriCure, Inc.2,9B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Construit à partir des documents déposés par West Pharmaceutical Services Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
